美国 · SEC FORM 4
EXELIXIS, INC.
EXEL · Nasdaq · CIK 0000939767 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
28 同一窗口内观察到的 Form 4 交易行
10 sales · 18 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 8 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-11-25 · Caligan Partners LP; JOHNSON DAVID EDWARD.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 28,183,726
- 上期报告
- 26,400,456
- 日均成交量
- 2,228,196
- 回补天数
- 12.7
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-11-25 | Caligan Partners LP; JOHNSON DAVID EDWARD | 买入 (P) | Common Stock | 27,532 | USD 43.12 | USD 1,187,180 | SEC 申报 ↗ |
| 2024-05-30 | Caligan Partners LP; JOHNSON DAVID EDWARD | 买入 (P) | Common Stock | 225,000 | USD 20.76 | USD 4,671,000 | SEC 申报 ↗ |
| 2024-05-28 | Caligan Partners LP; JOHNSON DAVID EDWARD | 买入 (P) | Common Stock | 200,000 | USD 20.32 | USD 4,064,000 | SEC 申报 ↗ |
| 2024-02-21 | Caligan Partners LP; JOHNSON DAVID EDWARD | 买入 (P) | Common Stock | 190,000 | USD 20.70 | USD 3,933,000 | SEC 申报 ↗ |
| 2023-11-27 | Caligan Partners LP; JOHNSON DAVID EDWARD | 买入 (P) | Common Stock | 120,409 | USD 21.61 | USD 2,602,038 | SEC 申报 ↗ |
Form 4 申报证据
87 transaction lines in the latest 365-day window; 824 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | 卖出 (S) | Common Stock | 9,812 | USD 53.66 | USD 526,512 | SEC 申报 ↗ |
| 2026-06-01 | WYSZOMIERSKI JACK L | 卖出 (S) | Common Stock | 3,925 | USD 50.55 | USD 198,409 | SEC 申报 ↗ |
| 2026-06-01 | Eckhardt Sue Gail | 卖出 (S) | Common Stock | 9,812 | USD 50.14 | USD 491,974 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Beckerle Mary C | 卖出 (S) | Common Stock | 9,812 | USD 53.66 | USD 526,512 | SEC 申报 ↗ |
| 2026-06-01 | WYSZOMIERSKI JACK L | 卖出 (S) | Common Stock | 3,925 | USD 50.55 | USD 198,409 | SEC 申报 ↗ |
| 2026-06-01 | Eckhardt Sue Gail | 卖出 (S) | Common Stock | 9,812 | USD 50.14 | USD 491,974 | SEC 申报 ↗ |
| 2026-05-27 | WYSZOMIERSKI JACK L | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Smith Julie | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | POSTE GEORGE | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | PAPADOPOULOS STELIOS | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Oliver Bob | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Heyman Tomas J. | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Freire Maria C | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Eckhardt Sue Gail | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Beckerle Mary C | 奖励/授予 (A) | Common Stock | 8,367 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-26 | Aftab Dana | 卖出 (S) | Common Stock | 43,451 | USD 50.35 | USD 2,187,758 | SEC 申报 ↗ |
| 2026-05-20 | Haley Patrick J. | 卖出 (S) | Common Stock | 32,110 | USD 49.81 | USD 1,599,399 | SEC 申报 ↗ |
| 2026-05-18 | Senner Christopher J. | 卖出 (S) | Common Stock | 34,901 | USD 50.00 | USD 1,745,050 | SEC 申报 ↗ |
| 2026-05-18 | MORRISSEY MICHAEL | 赠与 (G) | Common Stock | 124,047 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-18 | Hefti Brenda | 卖出 (S) | Common Stock | 6,625 | USD 50.21 | USD 332,641 | SEC 申报 ↗ |
| 2026-05-15 | Senner Christopher J. | 代扣税 (F) | Common Stock | 40,892 | USD 51.10 | USD 2,089,581 | SEC 申报 ↗ |
| 2026-05-15 | MORRISSEY MICHAEL | 代扣税 (F) | Common Stock | 128,497 | USD 51.10 | USD 6,566,197 | SEC 申报 ↗ |
| 2026-05-15 | Hefti Brenda | 代扣税 (F) | Common Stock | 6,411 | USD 51.10 | USD 327,602 | SEC 申报 ↗ |
| 2026-05-15 | Haley Patrick J. | 代扣税 (F) | Common Stock | 33,265 | USD 51.10 | USD 1,699,842 | SEC 申报 ↗ |
| 2026-05-15 | Aftab Dana | 代扣税 (F) | Common Stock | 30,578 | USD 51.10 | USD 1,562,536 | SEC 申报 ↗ |
| 2026-05-07 | POSTE GEORGE | 卖出 (S) | Common Stock | 60,000 | USD 45.71 | USD 2,742,600 | SEC 申报 ↗ |
| 2026-05-07 | Freire Maria C | 卖出 (S) | Common Stock | 20,634 | USD 46.00 | USD 949,164 | SEC 申报 ↗ |
| 2026-05-07 | Freire Maria C | 期权行权/转换 (M) | Common Stock | 20,634 | USD 19.77 | USD 407,934 | SEC 申报 ↗ |
| 2026-05-07 | Beckerle Mary C | 卖出 (S) | Common Stock | 7,712 | USD 48.45 | USD 373,646 | SEC 申报 ↗ |
| 2026-05-07 | Beckerle Mary C | 期权行权/转换 (M) | Common Stock | 3,856 | USD 23.24 | USD 89,613 | SEC 申报 ↗ |
| 2026-05-06 | MORRISSEY MICHAEL | 赠与 (G) | Common Stock | 109,676 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-26 | Senner Christopher J. | 奖励/授予 (A) | Common Stock | 52,018 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-26 | MORRISSEY MICHAEL | 奖励/授予 (A) | Common Stock | 160,437 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | EXEL |
| CIK | 0000939767 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 824 transaction lines from 2020-01-02 to 2026-08-10 5 P purchase lines · 235 S sale lines · 584 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.